Literature DB >> 27423613

Mortality in Hungarian patients with multiple sclerosis between 1993 and 2013.

Dániel Sandi1, Viktória Zsiros1, Judit Füvesi1, Zsigmond Tamás Kincses1, Zsanett Fricska-Nagy1, Gyula Lencsés2, László Vécsei3, Krisztina Bencsik4.   

Abstract

OBJECTIVE: We aimed to assess the causes of death, the mortality and survival time of MS patients in Hungary. PATIENTS AND METHODS: Between 1993 and 2013, 740 patients (10,303person-years) were treated at our Outpatients' Clinic, of which 121 died. The causes of death were established from the pathological records or the medical certificates of the cause of death. The standardized mortality ratios (SMR) were calculated. Survival time was assessed with Gehan-Breslow test.
RESULTS: Sixty-four percent of our patients died of MS-related causes. The SMR was 2.52. Primary progressive (PPMS) patients' SMR was higher (4.10) than initially relapsing patients' (RR/SPMS) was. There was no difference between the genders (2.46 for men vs 2.57 for women). The median survival time of woman was 3years longer (p<0.001). RR/SPMS patients' median survival (35years) was more than twice as long as PPMS patients' (14years). DISCUSSION: The frequency of the MS-related cause of death, SMR and the median survival times were mostly similar to previous results from Scandinavia and North-America, despite the very different socio-economic backgrounds of these areas which shows that the survival risk can solely be attributed to MS itself. These are the first data on the topic from Central-Eastern-Europe.
Copyright © 2016. Published by Elsevier B.V.

Entities:  

Keywords:  Cause of death; Hungary; Mortality; Multiple sclerosis; Survival time

Mesh:

Year:  2016        PMID: 27423613     DOI: 10.1016/j.jns.2016.06.035

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  1 in total

Review 1.  Proteomics in Multiple Sclerosis: The Perspective of the Clinician.

Authors:  Dániel Sandi; Zsófia Kokas; Tamás Biernacki; Krisztina Bencsik; Péter Klivényi; László Vécsei
Journal:  Int J Mol Sci       Date:  2022-05-05       Impact factor: 6.208

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.